GSK wins approval from the U.S. FDA for shingles vaccine
Date: 2017-10-24   Author: Sunil Hebbalkar  Category: #market

GSK wins approval from the U.S. FDA for shingles vaccine

GlaxoSmithKline (GSK) PLC, the British pharma giant, has apparently received the awaited green signal from the U.S. Food and Drug Administration for its new and enhanced shingles vaccine. As per reports, the Brentford-based joint venture is also hoping to win approval for another of its key products this year.

Sources claim that GSK’s shingles vaccine stood better than Zostavax, a product of Merck & Co, in the clinical trials carried out by the FDA. The fact that Shingrix - GSK’s shingles vaccine, has been approved by the FDA is one of the important acquittals of the company’s product pipeline. The vaccine is touted to emerge as one of most pivotal products in GSK’s portfolio, and has been claimed by analysts to collect a revenue of USD 1.36 billion by the end of 2023.

A month prior to the shingles vaccine approval, GSK made it to the headlines for having received the green signal for its three-in-one inhaler, designed to be used in chronic lung disease treatment. Post a series of approvals, further on, GSK hopes to launch a dual regimen drug for HIV. The U.S. regulatory bodies are apparently planning to carry out clinical trials for this groundbreaking drug regimen by the end of 2017.

Currently, it is being reported that Shingrix and Zostavax are the only available vaccines for shingles prevention, though the former has been declared to be more effective. Apart from the FDA, an advisory committee of the United States Centers for Disease Control and Prevention on immunization practices has also planned to cast its opinion regarding Shringrix.

Most analysts, it is reported, have been expecting a positive affirmation on Shringrix from the advisory committee, so that it can be liberally used for older adults. The expectation specifically borders on the fact that the elderly are more vulnerable to shingles and chicken pox owing to the recurrence of the varicella-zoster virus among older people.

For the record, GSK has also secured recommendation from the UK cost authorities to carry out a USD 700,000 worth gene therapy over the ‘bubble boy’ disease.



About Author


Sunil Hebbalkar

Sunil Hebbalkar

Sunil currently works as an content writer at AlgosOnline. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development department before switching his professional genre. Foll...

Read More

More from Sunil


Post Recommendents

Off-the-shelf Automated Workcells Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2024
Author: Partha Ray

The ' Off-the-shelf Automated Workcells market' study now available at MarketStudyReport.com, is a detailed sketch of the business sphere in terms of current and future trends driving the profit matrix. The report also indicates a pointwis...


Trends of Lab Single-mode Microplate Readers Market Reviewed for 2019 with Industry Outlook to 2024
Author: Partha Ray

The ' Lab Single-mode Microplate Readers market' research report is latest addition by Market Study Report, LLC, that elucidates relevant market and competitive insights as well as regional and consumer information. In a nutshell, the rese...


Worldwide Multi-mode Microplate Readers Market Forecast 2019-2024 Growth Drivers, Regional Outlook
Author: Partha Ray

Market Study Report, LLC, has added an exhaustive research study of the ' Multi-mode Microplate Readers market', detailing every single market driver and intricately analyzing the business vertical. This ' Multi-mode Microplate Readers...